Pyrrolidine ether derivatives as nk3 receptor antagonists

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 401/12 (2006.01) A61K 31/445 (2006.01) A61P 25/00 (2006.01) C07D 401/14 (2006.01)

Patent

CA 2720285

The present invention relates to a compounds of formula I wherein R1, R2, R3, R', Ar, o, n and m are as defined in the specification. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

La présente invention concerne des composés de formule I dans laquelle R1, R2, R3, R', Ar, o, n et m sont tels que définis dans la description. Il a été découvert que les composés de la présente invention sont des antagonistes des récepteurs NK3 à potentiel élevé pour le traitement de la dépression, de la douleur, de la psychose, de la maladie de Parkinson, de la schizophrénie, de lanxiété et du trouble dhyperactivité avec déficit de lattention (THADA).

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Pyrrolidine ether derivatives as nk3 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolidine ether derivatives as nk3 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine ether derivatives as nk3 receptor antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1837271

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.